Aquestive Therapeutics Inc
AQST
查看详细走势图
4.110USD
+0.270+7.03%
收盘 02/06, 16:00（美东）报价延迟15分钟
500.01M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+7.03%
5天
+39.32%
1月
-33.82%
6月
+4.58%
今年开始到现在
-36.38%
1年
+38.85%
查看详细走势图
TradingKey Aquestive Therapeutics Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Aquestive Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名49/159位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.22。中期看，股价处于下降通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Aquestive Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Aquestive Therapeutics Inc亮点
亮点风险
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
业绩高增长
公司营业收入稳步增长，连续3年增长20.72%
业绩增长期
公司处于发展阶段，最新年度总收入57.56M美元
估值合理
公司最新PE估值-5.86，处于3年历史合理位
机构加仓
最新机构持股68.88M股，环比增加0.08%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值8.09K
分析师目标
根据
9
位分析师
买入
评级
9.222
目标均价
+130.56%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Aquestive Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Aquestive Therapeutics Inc简介
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
公司代码AQST
公司Aquestive Therapeutics Inc
CEOBarber (Daniel R)
网址https://aquestive.com/
相关品种
